Clinical trialNCT00442598TerminatedPhase 2Interventional

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

SponsorEleison Pharmaceuticals LLC.Enrollment17Ovarian Cancer

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Primary Objectives: * To evaluate the effect of glufosfamide on the serum concentrations of CA125 in subjects with ovarian cancer * To evaluate the safety of weekly glufosfamide dosing in subjects with ovarian cancer as compared with every 21-day dosing Secondary objectives: * To evaluate the efficacy of glufosfamide in subjects with ovarian cancer as measured by objective response rate, duration of response, progression-free survival, and overall survival * To evaluate the pharmacokinetics of glufosfamide and isophosphoramide mustard during and after treatment Exploratory objective: * To correlate efficacy endpoints with expression of tumor-associated glucose transporter proteins

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Claire Verschraegen, M.D.
New Mexico Cancer Research Alliance
Principal Investigator
clinicaltrials.gov ↗
Daniela Matei, MD
Indiana University
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗
David Alberts, MD
University of Arizona
Principal Investigator
clinicaltrials.gov ↗
Jeffrey Goldberg, MD
Louisville Oncology Clinical Research Program
Principal Investigator
clinicaltrials.gov ↗
Krishnansu Tewari, MD
UCI Chao Family Comprehensive Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Larry Puls, MD
Gynecologic Oncology Research & Development, LLC
Principal Investigator
clinicaltrials.gov ↗
Michael Gordon, MD
Premiere Oncology of Arizona
Principal Investigator
clinicaltrials.gov ↗
Nashat Gabrail, MD
Gabrail Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Peter D Eisenberg, MD
California Cancer Center
Principal Investigator
clinicaltrials.gov ↗
William Robinson, MD
Harrington Cancer Center
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Premiere Oncology of Arizona
Scottsdale, Arizona, United States
Arizona Cancer Center
Tucson, Arizona, United States
California Cancer Center
Greenbrae, California, United States
Uci Chao Family Comprehensive Cancer Center
Orange, California, United States
Indiana University Cancer Center
Indianapolis, Indiana, United States
Louisville Oncology Clinical Research Program
Louisville, Kentucky, United States
New Mexico Cancer Care Alliance
Albuquerque, New Mexico, United States
Gabrail Cancer Center
Canton, Ohio, United States
Gynecologic Oncology Research & Development, Llc
Greenville, South Carolina, United States
Harrington Cancer Center
Amarillo, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Glufosfamide

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 Jan 2007
Primary completion: 30 Apr 2008
Completion: 30 Apr 2008
Last update posted: 10 Mar 2015
Registered enrollment: 17
Registry id: NCT00442598

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.